In the realm of contemporary science and healthcare, there exists an increasingly fervent excitement centered around an unassuming fungus that has captivated the imagination of researchers, clinicians, and the curious alike. Psilocybin, the mystical compound found in magic mushrooms, has emerged from the research periphery and stigma to take center stage in the world of medicine and scientific exploration.

Last week’s Phase 2 readout by Cybin Inc. (NASDAQ: CYBN) (deuterated psilocybin compound CYB003) was the latest such example of the tremendous critical mass of positive research is accumulating. But it surely won’t be the last. With dozens on clinical and pre-clinical efficacious studies in the books, psilocybin is accruing increasing confidence that it could be a frontline treatment for depression (and, possibly, off-label for co-morbid conditions) in the not-too-distant future.

With a resurgence of interest in the therapeutic potential of psilocybin on the upswing, …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.